Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recommend ....
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Limited reported standalone revenue of ₹31,079.70 lakhs for FY2025-26, up 2.7% from ₹30,249.64 lakhs in the prior year. However, net profit declined to ₹675.12 lakhs from ₹779.95 lakhs in FY2025 (down 13.4%). Consolidated net profit fell to ₹632.00 lakhs from ₹723.67 lakhs. The Board recommended a dividend of ₹1.20 per share (12%). Key corporate actions include a grant of 500,000 stock options to employees under ESOP 2025 and approval for preferential issue of 1,000,000 warrants to promoters (subject to shareholder approval). Auditors issued an unmodified opinion on both standalone and consolidated financials. Mr. Shreepada ML was appointed as Company Secretary replacing Mr. Abdul Basith.
The stock may see mixed reaction as revenue grew modestly while PAT declined sharply by 13%. The preferential warrants issue to promoters increases promoter holding, which could be viewed positively or as dilutive depending on conversion terms. The ESOP grant aligns employee interests with shareholders.